Ascendis Pharma

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ascendis Pharma reports strong revenue growth and market potential

Ascendis Pharma's financial performance in Q4 2022 showed revenue growth but operating losses, with a strong cash position.
Strengths lie in the TransCon technology platform, differentiation of products, and established commercial infrastructure.
Challenges include monitoring requirements, launch strategy comparisons, and market access strategies.
Opportunities arise from potential approvals, market dynamics, and clinical benefits of product candidates.

Ascendis Pharma reports robust Q1 revenue, faces regulatory challenges

Ascendis Pharma delivered a strong financial performance in Q1 2023, driven by revenue growth and strategic initiatives.
The company faces regulatory challenges and market dynamics that require resolution and strategic planning for sustained growth.
Opportunities for market expansion and product development exist through leveraging success factors and addressing regulatory hurdles.
Investor interest in Ascendis Pharma's future prospects is evident through analyst inquiries on growth expectations and market strategies.

Ascendis Pharma reports robust Q2 earnings amidst market challenges

Ascendis Pharma's Q2 performance reflects strong revenue generation and strategic advancements in key product pipelines, positioning the company for future growth.
Despite challenges in market shortages and regulatory processes, Ascendis Pharma's focus on innovation and market differentiation presents opportunities for expansion.
The company's emphasis on TransCon technology's unique benefits and market positioning underscores its competitive strength and growth potential in rare disease therapeutics.

Ascendis Pharma reports strong Q3 revenue growth and pipeline progress

Ascendis Pharma's Q3 2023 performance reflects revenue growth driven by SKYTROFA and progress in key pipeline programs.
The company's strategic focus on innovative therapies and patient-centric approaches positions it for future growth and market leadership.
While facing challenges like supply chain disruptions and market competition, Ascendis Pharma has opportunities for expansion and therapeutic innovation.
Balancing financial performance with pipeline advancement and commercial optimization will be crucial for Ascendis Pharma's sustainable success.

Ascendis Pharma excels in revenue growth and market leadership

Ascendis Pharma's strong performance in 2023, driven by SKYTROFA and TransCon PTH, positions the company for continued growth and success.
Despite challenges in market competition and treatment complexities, the company's strategic focus on patient outcomes and revenue growth is evident.
Opportunities in expanding therapeutic areas and maintaining market share stability offer potential for Ascendis Pharma's long-term success and value creation.

Ascendis Pharma reports robust Q1 performance and eyes global expansion

Ascendis Pharma's Q1 2024 performance reflects strong revenue growth, improved operational efficiency, and successful product launches, positioning the company for sustainable growth.
While facing challenges in market competition and financial targets, Ascendis Pharma's strategic strengths in product development and market expansion present growth opportunities.
The company's focus on innovation, commercial execution, and market positioning underscores its potential to become a leader in growth disorders and metabolic diseases.
Investors should monitor Ascendis Pharma's progress in achieving cash flow breakeven, expanding product portfolios, and navigating regulatory landscapes for future growth potential.

Ascendis Pharma excels in Q2 with YORVIPATH approval and revenue growth

Ascendis Pharma's Q2 2024 earnings call highlighted strong financial performance, successful product approvals, and strategic commercialization efforts.
The company faces challenges in pricing strategies, market dynamics, and ensuring patient uptake, but opportunities exist in expanding market reach and advancing pipeline programs.
Overall, Ascendis Pharma's focus on innovation, patient support, and financial growth positions it well for continued success and market leadership in the biopharmaceutical industry.

Ascendis Pharma reports robust Q3 performance and eyes strategic growth

Ascendis Pharma showcased strong performance across its product portfolio and pipeline candidates, with notable revenue growth and promising clinical outcomes.
While facing challenges in market penetration and regulatory processes, the company is well-positioned to capitalize on growth opportunities through strategic collaborations and upcoming product launches.
By navigating challenges effectively and leveraging opportunities, Ascendis Pharma aims to drive sustainable growth and value creation in the pharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ascendis Pharma A/S (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?

-   Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S (ASND) Q2 2023 Earnings Conference Call September 5, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Executive Vice President and Chief Financial Officer Conference Call Participants Li Watsek - Cantor Paul Choi - Goldman Sachs Andreas Argyrides - Wedbush Securities David Lebovitz - Citi Leland Gershell - Oppenheimer Operator Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript

COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2023 and provided business updates.

Ascendis Pharma Reports Second Quarter 2023 Financial Results

- Approximately 50% of Phase 3 PaTHway Trial patients with eGFR < 60 mL/min/1.73m 2 , the threshold for kidney dysfunction, receiving TransCon PTH experienced eGFR improvement to above 60 mL/min/1.73m 2 .

New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism

The average of price targets set by Wall Street analysts indicates a potential upside of 41.4% in Ascendis Pharma A/S (ASND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should Know

COPENHAGEN, Denmark, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in three upcoming investor conferences.

Ascendis Pharma A/S Announces Three Upcoming Investor Presentations

TSX: ASND www.ascendantresources.com All matters overwhelmingly approved by shareholders TORONTO , Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX: ASND) (OTCQB: ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company.

Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday, September 5, 2023, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and webcast on September 5, 2023, at 4:30 p.m. Eastern Time (ET) to discuss second quarter 2023 financial results and operations.

Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023

The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35%

- Oral presentation of results showed sustained improvements through Week 52,  as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion  of the Phase 3 PaTHway Trial

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

- Endocrinology clinical development progress and research i n growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome will be highlighted

Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023

COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13.

Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

– Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH (palopegteriparatide) for eligible adult patients with hypoparathyroidism

Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany

–   TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will host an Oncology program update for the investment community on Wednesday, May 31, 2023 in New York from 10:00 a.m. to 12:00 p.m. Eastern Time.

Ascendis Pharma to Host Oncology Program Update on May 31

COPENHAGEN, Denmark, May 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will present clinical and research outcomes in hypoparathyroidism and growth hormone deficiency, and host informational booth and events, at ECE 2023, the European Congress of Endocrinology being held May 13-16 in Istanbul, Turkey. ECE gathers international professionals to share the latest science and clinical practice across the fields of endocrinology and metabolism.

Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023

COPENHAGEN, Denmark, May 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a virtual fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9.

Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference

The US Food and Drug Administration (FDA) did not grant its approval to Ascendis Pharma's experimental hormone disorder therapy, but the company's stock has soared Monday nonetheless.  The therapy, called TransCon OTH, is designed to treat adult patients with a disorder called hypoparathyroidism, in which the body produces abnormally low levels of parathyroid hormone.

Ascendis Pharma shares pop after FDA rejects hormone therapy application but not the underlying clinical data

Ascendis has seen a big uptake in sales for its human growth hormone therapy. The company said it plans to request a meeting with the FDA regarding hyperthyroidism therapy TransCon PTH.

Why Shares of Ascendis Pharma Are Climbing Monday

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript.

Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript

• Focused on bringing TransCon™ PTH to the U.S. and EU markets as soon as possible • 145 of 154 clinical trial participants continue treatment with TransCon PTH for up to 3 years, and U.S. Expanded Access Program continues to enroll new patients • SKYTROFA ® * revenue reached €31.6 million in the first quarter of 2023; Ascendis expects full-year 2023 SKYTROFA revenue of €150 - €160 million • Company to hold Oncology program update on Wednesday, May 31 in New York City • Conference call today at 4:30 pm ET COPENHAGEN, Denmark, April 27, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2023 and provided a business update. “Based on our clinical experience with TransCon PTH to date, we have seen the improvement in the lives of many patients living with hypoparathyroidism and we are committed to working with regulatory authorities in the U.S. and EU to bring it to market as soon as possible,” said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer.

Ascendis Pharma Reports First Quarter 2023 Financial Results

NEW YORK , April 22, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ascendis Pharma ("Ascendis" or the "Company") (NASDAQ: ASND). If you suffered losses exceeding $50,000 investing in Ascendis stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

ASCENDIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ascendis To Contact Him Directly To Discuss Their Options

Ascendis Pharma: A Promising Diversification Play.

Ascendis Pharma: A Promising Diversification Play

NEW YORK , April 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Ascendis Pharma A/S ("Ascendis" or the "Company") (NASDAQ: ASND).  Such investors are advised to contact Robert S.

News for Ascendis Pharma Stock (ASND)